(Q46548604)

23 December 2017

title

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma (English)

1 reference

23 December 2017

1 reference

5

Ravi Salgia

1 reference

23 December 2017

10

Pasi A Jänne

1 reference

23 December 2017

David M Jackman

1

1 reference

23 December 2017

Hedy L Kindler

2

1 reference

23 December 2017

Beow Y Yeap

3

1 reference

23 December 2017

Panos Fidias

4

1 reference

23 December 2017

Joan Lucca

6

1 reference

23 December 2017

Linda K Morse

7

1 reference

23 December 2017

Patricia A Ostler

8

1 reference

23 December 2017

Bruce E Johnson

9

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

23 December 2017

published in

Cancer

1 reference

23 December 2017

volume

113

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

808-814

1 reference

23 December 2017

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

Malignant Mesothelioma: Global Incidence and Relationship with Asbestos

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Phase II trial of ZD0473 as second-line therapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23617

7 January 2021

Identifiers

DOI

10.1002/CNCR.23617

1 reference

23 December 2017

1 reference

23 December 2017